Vincristine sulfate

For research use only.

Catalog No.S1241 Synonyms: Leurocristine

60 publications

Vincristine sulfate Chemical Structure

CAS No. 2068-78-2

Vincristine sulfate (Leurocristine) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 90 In stock
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Vincristine sulfate has been cited by 60 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Vincristine sulfate (Leurocristine) is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 MkfzR4VtdCCYaXHibYxqfHliQYPzZZk> M2nsS|AuOC53IN88US=> NGPvSpIzPCCq MVzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M3nRU|I2PjZ|N{[5
HepG2-HBV1.1 NFz4W|JCeG:ydH;zbZMhSXO|YYm= MX6wMVAvPSEQvF2= M33JOFI1KGh? MoXGbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= Mn3SNlU3PjN5Nkm=
HepG2.2.15 MkHGSpVv[3Srb36gRZN{[Xl? NEOw[5IxNjFizszN NXHyb3A3OjRiaB?= Mmn0dJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u MkfxNlU3PjN5Nkm=
HepG2-HBV1.1 NH\FRllHfW6ldHnvckBCe3OjeR?= MXmwMlEh|ryP MVGyOEBp NX;PNmZleHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v Mk\UNlU3PjN5Nkm=
HepG2-HBV1.1 NX7FOlFFTnWwY4Tpc44hSXO|YYm= MYCwMlEh|ryP NWPHNIJLPDhiaB?= MkjmdJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW|IFThcoUheGG{dHnjcIV{ MnL3NlU3PjN5Nkm=
HepG2-HBV1.1 M1zmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPrbZo4OC5zIN88US=> MUexMVUh\A>? NGrCOGhqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 NX33bllMOjV4NkO3Olk>
HepG2-HBV1.1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnFeVBYOC5zIN88US=> NYDOXINyOS13IHS= NYrPSFRrcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=> NUT0dWdxOjV4NkO3Olk>
HepG2-HBV1.1 M2r6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWwMlEh|ryP NXm2VoxIOTJvN{KgbC=> NUO3[5E4cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCCVLYDoZZNm MY[yOVY3Ozd4OR?=
HepG2-HBV1.1 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nuVlAvOSEQvF2= MmTPNVIuPzJiaB?= M1O2W4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> MljxNlU3PjN5Nkm=
Raji NXjEW49QTnWwY4Tpc44hSXO|YYm= MUOwMlXDqM7:TR?= MV:3NkBp M3\lV4Fjd2yrc3jld{BifXSxcHjh[5nDqA>? MkTNNlU1PDZ|N{e=
SK-MEL-28  MWHGeY5kfGmxbjDBd5NigQ>? MXGzNEBvVQ>? NVfCe5E{PiCq MYTpcoR2[2W|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>? NXHD[lBQOjV|MUOwNVA>
H157 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwMEOgxtEhOC5yNDDtbZUzVQ>? NVe5fYdROjV{NUe5NVE>
Jurkat MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPGN3VbOS1|IH7N MX20POKhcA>? NELReIhFVVOR NI\ibINl\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 MXqyOVE2PjF2Nh?=
CEM M2PWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;hNpIyNTNibl2= MUO0POKhcA>? NYLOWnlRTE2VTx?= NFvkco9l\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 M3TBdVI2OTV4MUS2
P12 NFS2b5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixMVMhdk1? M3;ORVQ5yqCq NETUZ3lFVVOR MWrk[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 NInJT2YzPTF3NkG0Oi=>
KB NEKxd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqyeYxKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN M1LaOFI2ODV6NUK2
KBv200 (ABCB1) MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vVc2lEPTB;MD6zOFYzKMLzIECuNFA3PiEQvF2= M3zje|I2ODV6NUK2
SUDHL6  NXjxdGxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKx5qCK|ryP MYS0PE84OiCq NGHEWpFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 M4LQWFI1QTZzNkC0
SUDHL6  NWfvZ5EzTnWwY4Tpc44hSXO|YYm= NU\BfnZzOeLCid88US=> NFTF[GM4OiCq M4nhXYlv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF? M2\wNlI1QTZzNkC0
HCT-116 NWLPSlRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\sdWdKPTB;NTDuUS=> MoXzNlQ6Ojd6NUe=
SKNBe2C M{fjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LmOGlEPTB;M{KuPOKyPC5yIH7N MV:yOFkzOTl{MB?=
IGNR91 M1;pTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TF[WlEPTB;MkSuN:KyOS55IH7N M4\KeFI1QTJzOUKw
SKNAS MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXL[llKSzVyPUGuOeKyOC5{IH7N NGDUe|EzPDl{MUmyNC=>
LAN1 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;vTWM2OD1{LkRCtVAvOiCwTR?= NYLQclluOjR7MkG5NlA>
SHSY5Y M3PMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLrPFhKSzVyPUiuNuKyOC54IH7N NFTMUI0zPDl{MUmyNC=>
A549-WT MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\sTWM2OD1zOT60N|chyrFiMD61PVQhKG6P NUL5THVWOjR6NUi4Nlc>
A549-R MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjrdZI3UUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N NUDMe4hCOjR6NUi4Nlc>
MCF-7-WT M{XEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF5Lke1NkDDuSByLkKxPEAhdk1? MmfQNlQ5PTh6Mke=
MCF-7-R NWHmW203T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:zfmp2UUN3ME21MlU{QSEEsTCwMlE1PCBibl2= NV;KdnB3OjR6NUi4Nlc>
A549-R NVr3cIxHS3m2b4TvfIlkcXS7IFHzd4F6 MWTJR|UxRTF{LkG3PEDDuSByLkOzN{BvVQ>? NXvqRlRROjR6NUi4Nlc>
MCF-7-R NFH1eIZEgXSxdH;4bYNqfHliQYPzZZk> NEP2W|dKSzVyPUWuOVM6KMLzIECuNVQ1KG6P MVmyOFg2QDh{Nx?=
SW620 NILFdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDQXHBQUUN3ME23MlgxKMLzIECuNFghdk1? MWGyOFczPjd|OR?=
SW620/AD300 M3[5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV21SJVSUUN3ME25NFkvPjBiwsGgPE46OSCwTR?= NFq2OoMzPDd{NkezPS=>
HEK293/pcDNA3.1 MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36yNGlEPTB;MT60OUDDuSByLkKwJI5O NGnzV|kzPDd{NkezPS=>
HEK293/ABCC1 MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zNemlEPTB;MUmuNlkhyrFiMj6wPEBvVQ>? Mmf0NlQ4OjZ5M{m=
TCC NWPuU3c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofsNlQhcA>? MnLGTWM2OD15MDDuUS=> MnTxNlQ4OTZ7NES=
TCC NFLSUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLORnlGPDhiaB?= MkDjTWM2OD13MDDuUS=> MWGyOFcyPjl2NB?=
HepG2/ADM Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTlXIRKSzVyPUKuO|g3O8LzMD6yN|cyKM7:TR?= MmnINlQ4ODR3NU[=
HepG2 NIf2PGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEGxOeKyOC5yMEG3JO69VQ>? MWmyOFcxPDV3Nh?=
MCF-7/ADR MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH36U5pKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?= MX:yOFcxPDV3Nh?=
MCF-7 M3rGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HaPGlEPTB;MD6wNVU6yrFyLkCwOlIh|ryP M2jDc|I1PzB2NUW2
A-172  M1\uZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqwMlHDqM7:TR?= MXGyOE84OiCq NXfwXJV1cW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? NEC4XXAzPDV|MEKzOS=>
U-251MG NV7RbZgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O0[FAvOcLizszN MoXENlQwPzJiaB?= M3L0[IlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> NWDwTHBjOjR3M{CyN|U>
DLD-1 NYrrXlFyTnWwY4Tpc44hSXO|YYm= Mne3NVAxKG6P NWrWfpExPDhiaB?= NVzwVYgzeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi Mn;LNlQ1ODN2NUO=
CCD18Co MXPGeY5kfGmxbjDBd5NigQ>? NFHPXY8yODBibl2= MWi0PEBp NGm3b3hxem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB? MnXTNlQ1ODN2NUO=
DLD-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvFfmgxNTFyMECgcm0> MVS0PEBp NH;aS4FqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NXK4WmxUOjR2MEO0OVM>
CCD18Co NIC5XnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXn1U4l{OC1zMECwJI5O MVS0PEBp M{TkRYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MUCyOFQxOzR3Mx?=
HepG2 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWeyOEBp MmPmTWM2OD13Mj615qCK|ryP Mo\xNlQ{PDF4OEi=
HEK293/pcDNA3.1 M17YTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTxTWM2OD1yLkCwOOKyOC5yMECzJO69VQ>? NU\BVYR4OjR{OES3PFM>
HEK293/MRP1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEW1xtExNjBzMkCg{txO M4jsVlI1Ojh2N{iz
Ramos MnnGRZBweHSxc3nzJGF{e2G7 MYey5qCK|ryP NEThe401QCCq NY\hZnRncW6mdXPld{A{PC54JdMxNU46OiViYYDvdJRwe2m| NEX0cpYzPDJ3NkS5NS=>
NCI-H1299/pcDNA3 M{nUXmNmdGxiVnnhZoltcXS7IFHzd4F6 MnXvNE0zOCCwTR?= NYKxfYtXQTZiaB?= MmOxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NWr5fZF{OjRzN{ewNVI>
H1299/ICAM-3 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX:wMVIxKG6P MUi5OkBp MlLqbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M1jrXlI1OTd5MEGy
NCI-H1299/pcDNA3 NXjnPZdYTnWwY4Tpc44hSXO|YYm= M4rPflEwPS9zMD:yNOKhdk1? NVH3[5E1QTZiaB?= NWnHcI9KcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? M3q3SlI1OTd5MEGy
H1299/ICAM-3 M2\ldGZ2dmO2aX;uJGF{e2G7 NYW5e2dOOS93L{GwM|IxyqCwTR?= MXW5OkBp MmDobY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=> M3\Oe|I1OTd5MEGy
W1 M3T6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HFN2lEPTB;MD6wNFMzKM7:TR?= NI\OblIzPDF2MEG3Oi=>
W1VR M4DlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojqTWM2OD1yLkC1OkDPxE1? NV;RWnVYOjRzNECxO|Y>
K562 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PPO2lEPTB;MD6wN|IhyrFiMD6wNFEhKM7:TR?= MmDLNlQyOzV7M{e=
K562/ADR MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXoTWhPUUN3ME2zMlI3OSEEsTCwMlQyOiEQvF2= NUL4NFg6OjRzM{W5N|c>
K562 MoHqRZBweHSxc3nzJGF{e2G7 NITKWmsxNjNizszN M{i5W|I1KGh? MWHpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MYGyOFE{PTl|Nx?=
K562/ADR MULBdI9xfG:|aYOgRZN{[Xl? M1TjcFMh|ryP MXmyOEBp NX;IN2RycW6mdXPld{BieG:ydH;zbZM> MX[yOFE{PTl|Nx?=
A549 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\EXndKSzVyPUCuNVAhyrFiMD6wN{DPxE1? M4LCO|I{QTdzMEe1
K562 M{[x[2NmdGxiVnnhZoltcXS7IFHzd4F6 M2[wSVMvPzYkgKO2NOKhdk1? NFzzfZI4OsLiaNMg MX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 Mn3TNlM5Pzd{MkO=
lucena MlfRR4VtdCCYaXHibYxqfHliQYPzZZk> M1\JNlMvPzYkgKO2NOKhdk1? NEXTV4E4OsLiaNMg Monrco8h\W[oZXP0 MVuyN|g4PzJ{Mx?=
FEPS MnHER4VtdCCYaXHibYxqfHliQYPzZZk> NYHuTGpmOy55NfMAl|YxyqCwTR?= Ml7QO|LDqGkEoB?= MYHuc{Bm\m[nY4S= MU[yN|g4PzJ{Mx?=
A2780 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG2S4NUUUN3ME2zMlUhdU1? NVvxTmh6OjN6MkmyNFM>
ACHN NHrjNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\VTWM2ODxyLkGgcW0> MWKyN|gzQTJyMx?=
U-937 NHzxT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRDN2IH7N NYXXNZdlOjN6MkmyNFM>
Jurkat MXvBdI9xfG:|aYOgRZN{[Xl? MWK1xsDPxGdxbX|CpC=> M2XLTlI1KGh? MXPpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NF\hflkzOzhzMESwPS=>
Jurkat MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjETmQxPcLizsznM41tyqB? M1fGNVI1KGh? NU\pRVQ6[XK{ZYP0JGp2emujdDDj[YxteyCrbjDHNk9OKHCqYYPl Mm\oNlM5OTB2MEm=
Hep-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMEVCtVAvODFizszN NED0O|AzOzd6MESyOC=>
Hep-2/v NXexSZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPJTWM2OD1zLklCtVAvOjBizszN NXe3Xop5OjN5OEC0NlQ>
SGC-7901 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TrWlAuOTBizsznM41t M1j0eVI1NzR6L{eyJIg> NUHQXJpvcW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz MVqyN|c1OzV5Mh?=
SGC-7901/VCR NUPrUGJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTDU5RKOC1zMDFOwIcwdWx? MWGyOE81QC95MjDo MljpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MnrJNlM4PDN3N{K=
SGC-7901 MknNRZBweHSxc3nzJGF{e2G7 M4P2N4lv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NYLGSmo{OjN5NEO1O|I>
SGC-7901/VCR M2S0fWFxd3C2b4Ppd{BCe3OjeR?= NF\RfWFqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NWT6eVRrOjN5NEO1O|I>
KB-3-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTqXJBoUUN3ME2xMlY3KMLzIECuNVYzKM7:TR?= M2HwXVI{Pjd|NES1
KB-C2 NXLXfItST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJyMj61OkDDuSB2Mj60PFEh|ryP MlThNlM3PzN2NEW=
KB-3-1 NUDOfnFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwMk[gxtEhOC5yMkeg{txO NUP4T2k3OjN4N{O0OFU>
KB-V1 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX5UZNEUUN3ME2yNFgvQDViwsGgNlAvPCEQvF2= NVT0NGpEOjN4N{O0OFU>
HEK293/pcDNA3.1 NYPQTlhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrvTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>? NV63PHN6OjN4N{O0OFU>
HEK293/ABCB1 M3vtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C4dWlEPTB;M{WxNk45KMLzIEO3PE4{QTFizszN MlLSNlM3PzN2NEW=
A549/EGFP  Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\LNE4xOS1zMECwJO69VQ>? NVHBUYZxUUN3ME24Ok44KMLzIEK5MlEh|ryP M4i2blI{PjN2Mkiy
A549/Slug MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nsdlAvODFvMUCwNEDPxE1? MofETWM2OD17LkegxtEhOy5zIN88US=> MoSwNlM3OzR{OEK=
JFCR39  NFjUV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jhXVEhyrWP NIXX[mYzPCCq M3Px[GROW09? MmfScYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG|ZTDj[Yxtew>? MYCyN|U6QDJ5Nh?=
A549 MX7GeY5kfGmxbjDBd5NigQ>? NXzHZo43OTByIH7N M{\iclE3KGh? M4nKdGROW09? MYLs[YFleyC2bzDhJIxwe3Nib3[gcYlkem:2dXL1cIV{ MYqyN|U6QDJ5Nh?=
SGC7901 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwMkdihKnDueLCiUCuNVEh|rypL33s MmrMNlM2PjR2OEK=
SGC7901/LV-NC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXuTWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=> MoLQNlM2PjR2OEK=
SGC7901/LV-SGO1 NHTENGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPLTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=> NH\vdVczOzV4NES4Ni=>
SGC7901/VCR MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|U{RTJyLkWz5qCKyrIkgJmxMlk3KM7:Zz;tcC=> NVznRY52OjN3NkS0PFI>
SGC7901/VCR-NC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTDVFBDUUN3ME2xPU45PuLCidMx5qCKOi5yMTFOwIcwdWx? M4\PUFI{PTZ2NEiy
SGC7901/VCR-si-SGO1 NEe2TWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\Wbo1KSzVyPU[uNVjjiIoEsfMAjVEvODNizsznM41t NFTRVpAzOzV4NES4Ni=>
SGC7901/ADR M3e0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfJRmJvUUN3ME23Mlg26oDLwsJihKkxNjZ2IN88[{9udA>? MWCyN|U3PDR6Mh?=
SGC7901/ADR-NC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3PSWpKSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41t MmfONlM2PjR2OEK=
SGC7901/ADR-si-SGO1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoL2TWM2OD1|LkS25qCKyrIkgJmwMlI6KM7:Zz;tcC=> NFG1dFczOzV4NES4Ni=>
SH-SY5Y  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rSR|AvODBzLUGwJO69VQ>? NFnOU3kzPCCq NEnqSmRKSzVyPUCuNVE{yrFyLkCxNkDPxE1? Mn7yNlMyOjlyNkW=
SH-SY5Y  MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqwMlAxOS1zMDFOwG0> M1rpWlQ5KGh? NX2xVZpnUUN3ME2wMlA4QMLzMD6wNFkh|ryP NV\1fnFkOjNzMkmwOlU>
SH-SY5Y  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[wMlAxOS1zMDFOwG0> NUTmVYZ5PzJiaB?= M2PUc2lEPTB;MD6wOVHDuTBwMEC4JO69VQ>? M123SlI{OTJ7ME[1
SH-SY5Y M37qeWFxd3C2b4Ppd{BCe3OjeR?= MXywMlEh|ryP M4DM[FAuOjRiaB?= NH7lTYhqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCVSD3TXVV[KGOnbHzzJIZwdGyxd3nu[{Bk\WyuIHP5Z4xmKGG{cnXzeEBifCC2aHWgS|IwVSCyaHHz[S=> NEnsOm4zOzF{OUC2OS=>
SH-SY5Y NELjRoRCeG:ydH;zbZMhSXO|YYm= MmfSNE4yKM7:TR?= MUmwMVI1KGh? MoC5bY5lfWOnczDtbZRwfGmlIHHydoV{fMLi NUW3XWVIOjNzMkmwOlU>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; 

PubMed: 26156322     


MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine

26156322
Growth inhibition assay
Cell viability ; 

PubMed: 26156322     


MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively.  Cell viability was measured by MTT assay.

26156322
In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine
Smiles CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04448834 Not yet recruiting Drug: Blinatumomab B-cell Acute Lymphoblastic Leukemia David Rizzieri MD|Amgen|Acrotech Biopharma|Duke University September 1 2020 Phase 2
NCT03981510 Recruiting Diagnostic Test: 3D-Transit Constipation|Childhood Acute Lymphoblastic Leukemia|Neurofibromatosis 1|Chronic Constipation With Overflow University of Aarhus June 2019 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID